Patient education for those seeking peptide receptor radionuclide therapy


Session type:

Josh Mailman1
1NorCal CarciNET, Oakland, USA


Neuroendcrine Tumors (NETs) are rare tumors that have an incidence of 2.5 cases per 100,000 population. Diagnostic and treatment choices have evolved over the last two decades to include molecular imaging and therapies. In the last decade Peptide Receptor Radionuclide Therapy (PRRT) has become more common place in the management of NETs in Europe but it's use is still in it's infancy in North America. In 2011 an English website was launched that focused exclusively on PRRT. Visitors from around the world have made the website a destination for patient centered information on PRRT treatment and Ga68 imaging.


The website collects de-identified data on external web search as well as search done on site. We will examine the search history to better understand what patients are interested in regards to molecular therapies and imaging for NETs.


Over 24,000 visits and 5,000 search will be analyzed to better understand what type of information patients are looking for when consider PRRT. The results will be analyzed by search term and type of article (educational vs informational) and presented in table form.


With over 1,500 unique visitors to an independent website dedicate to PRRT information it is clear that patient, caregivers and other medical professionals are interested in PRRT. Centers offering this type of treatment should be offering their patient community more detailed information on PRRT and how it is administered.